IQV · Iqvia Holdings Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 28, 2026TL;DR. IQVIA's Q2 2026 results exceeded the high end of guidance across revenue, adjusted EBITDA, and adjusted EPS, driven by accelerating organic growth, record R&D bookings of $3.15B (1.22x book-to-bill), and strong free cash flow, prompting the company to raise full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.
- + Organic growth accelerated to 6% year-over-year, roughly three times the prior-year rate.
- + Free cash flow grew 23.3% year-over-year on strong operating cash flow.
- + EBP funding of $35B in Q2 was more than double the prior-year quarter, supporting sustained R&D demand.
- − Foreign exchange is now only a ~20 bps tailwind vs. ~100 bps previously assumed, dragging reported growth.
- − Pass-through revenue growth remains a non-operational margin headwind.
- − Full-year 2026 adjusted EBITDA margin guidance reconfirmed as flat at ~23.2%, despite operational productivity gains.
- − Net leverage ratio remains elevated at 3.59x trailing twelve-month adjusted EBITDA.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cost of revenues, exclusive of depreciation and amortization (% of revenues) | 67.1% | Three Months Ended June 30, 2026 filing | — |
| Depreciation and amortization (% of revenues) | 6.7% | Three Months Ended June 30, 2026 filing | — |
| Selling, general and administrative expenses (% of revenues) | 13.1% | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IQV
this stock
Iqvia Holdings Inc.
|
$45.12B | +19.3% | +41.6% | 33.6 | 2.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IQV | +0.4% | +4.1% | +59.1% | +2.9% | +19.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +1.0% | +4.0% | +46.9% | +3.5% | +7.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.